{"id":"20a03c79-d46c-5168-8282-fd261798466c","stable_key":"548ab9d6-3a9b-5bed-879c-17d03813b636:b2-tt-bp-rechallenge","predicate":"lowered_pressure_in_repeat_intervention","statement":"A four-year follow-up with reversed intervention assignments in 31 TT participants again reported BP lowering during riboflavin administration.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"8b553f80-27cd-5e7b-be51-d67a0d689fb2","mechanism_event_label":"The earlier participants were studied again; this supports repeat responsiveness but is not an independent population or continuous four-year treatment.","subject":{"id":"86eb1eee-a8d1-539c-8c17-0911f69b6f1b","slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"},"object":{"id":"9eda1162-1823-5c43-8e7d-4f2e4858c353","slug":"blood-pressure","display_name":"Arterial blood pressure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"8b553f80-27cd-5e7b-be51-d67a0d689fb2","stable_key":"548ab9d6-3a9b-5bed-879c-17d03813b636:b2-tt-bp-rechallenge-event","event_type":"observed_intervention","label":"The earlier participants were studied again; this supports repeat responsiveness but is not an independent population or continuous four-year treatment.","description":"A four-year follow-up with reversed intervention assignments in 31 TT participants again reported BP lowering during riboflavin administration.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9fc32b1a-0f08-544c-a361-1c728203b6ec","slug":"mthfr","display_name":"Methylenetetrahydrofolate reductase / MTHFR","entity_type_key":"protein"},"role":"genotype_context","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"86eb1eee-a8d1-539c-8c17-0911f69b6f1b","slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"9eda1162-1823-5c43-8e7d-4f2e4858c353","slug":"blood-pressure","display_name":"Arterial blood pressure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"experimental_model","value_text":"Four-year follow-up of 83 prior participants; 31 TT participants underwent repeat intervention with former treatment assignments reversed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"1.6 mg/day for 16 weeks in 2004 and again in 2008 with reversed allocations; not four years of continuous supplementation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Follow-up selection, small TT sample and changing antihypertensive treatment limit inference; overlaps earlier cohort.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Riboflavin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The earlier participants were studied again; this supports repeat responsiveness but is not an independent population or continuous four-year treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[b2-wilson2012] Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up (2012). https://pubmed.ncbi.nlm.nih.gov/22277556/ DOI: 10.3945/ajcn.111.026245","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Human clinical setting","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"ffe69c2c-8036-5da5-bb3b-0cf6ac97068a","evidence_kind":"source_excerpt","locator":"Lines 1540-1550","start_line":1540,"end_line":1550,"excerpt":"### b2-tt-bp-rechallenge\nA four-year follow-up with reversed intervention assignments in 31 TT participants again reported BP lowering during riboflavin administration.\nCondition category: machinery_impairment\nnutrient_topic: Riboflavin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The earlier participants were studied again; this supports repeat responsiveness but is not an independent population or continuous four-year treatment.\norganism: Homo sapiens\ntissue_or_cell_type: Human clinical setting\nexperimental_model: Four-year follow-up of 83 prior participants; 31 TT participants underwent repeat intervention with former treatment assignments reversed.\nlimitations: Follow-up selection, small TT sample and changing antihypertensive treatment limit inference; overlaps earlier cohort.\nexposure: 1.6 mg/day for 16 weeks in 2004 and again in 2008 with reversed allocations; not four years of continuous supplementation.\n[b2-wilson2012] Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up (2012). https://pubmed.ncbi.nlm.nih.gov/22277556/ DOI: 10.3945/ajcn.111.026245","model_system":"Four-year follow-up of 83 prior participants; 31 TT participants underwent repeat intervention with former treatment assignments reversed.","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [b2-wilson2012] Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up (2012). https://pubmed.ncbi.nlm.nih.gov/22277556/ DOI: 10.3945/ajcn.111.026245","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"4f7c9578-82bf-5e2d-b5c4-72a79fb4f6af","stable_key":"import-548ab9d6-3a9b-5bed-879c-17d03813b636","title":"Riboflavin: mechanisms, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"680cb6bc8249877f2410f551807f10d390fdd719014137d7414ba3420e29228d","revision_id":"7a61e299-908d-5372-860b-99ed190f9d7a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}